EP3968948A1 - Cosmetic composition with combined filler and skin regenerative effect - Google Patents
Cosmetic composition with combined filler and skin regenerative effectInfo
- Publication number
- EP3968948A1 EP3968948A1 EP19758620.9A EP19758620A EP3968948A1 EP 3968948 A1 EP3968948 A1 EP 3968948A1 EP 19758620 A EP19758620 A EP 19758620A EP 3968948 A1 EP3968948 A1 EP 3968948A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- skin
- cosmetic
- anyone
- proline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 104
- 239000000945 filler Substances 0.000 title claims abstract description 45
- 239000002537 cosmetic Substances 0.000 title claims abstract description 39
- 230000001172 regenerating effect Effects 0.000 title abstract description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 21
- 230000002500 effect on skin Effects 0.000 claims abstract description 11
- 229920002674 hyaluronan Polymers 0.000 claims description 24
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 22
- 229960003160 hyaluronic acid Drugs 0.000 claims description 22
- 230000037303 wrinkles Effects 0.000 claims description 15
- 235000001014 amino acid Nutrition 0.000 claims description 14
- 229940024606 amino acid Drugs 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 102000012422 Collagen Type I Human genes 0.000 claims description 13
- 108010022452 Collagen Type I Proteins 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- 230000003712 anti-aging effect Effects 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- RNKSNIBMTUYWSH-YFKPBYRVSA-N L-prolylglycine Chemical compound [O-]C(=O)CNC(=O)[C@@H]1CCC[NH2+]1 RNKSNIBMTUYWSH-YFKPBYRVSA-N 0.000 claims description 6
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 claims description 6
- 108010087924 alanylproline Proteins 0.000 claims description 6
- KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 claims description 6
- 108010077515 glycylproline Proteins 0.000 claims description 6
- 108010029020 prolylglycine Proteins 0.000 claims description 6
- WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical group C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 claims description 5
- 241000255789 Bombyx mori Species 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 230000008047 biological aging effect Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 238000010254 subcutaneous injection Methods 0.000 claims description 4
- 239000007929 subcutaneous injection Substances 0.000 claims description 4
- 230000009261 transgenic effect Effects 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- 235000009582 asparagine Nutrition 0.000 claims description 3
- 229960001230 asparagine Drugs 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- 235000004554 glutamine Nutrition 0.000 claims description 3
- 235000005772 leucine Nutrition 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 210000004872 soft tissue Anatomy 0.000 claims description 2
- 206010040954 Skin wrinkling Diseases 0.000 claims 2
- 230000004071 biological effect Effects 0.000 abstract description 10
- 210000003491 skin Anatomy 0.000 description 50
- 238000000034 method Methods 0.000 description 19
- 238000011049 filling Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 9
- 230000009759 skin aging Effects 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000002513 implantation Methods 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- -1 OH-Proline Chemical compound 0.000 description 4
- 206010051246 Photodermatosis Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000008845 photoaging Effects 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 208000032544 Cicatrix Diseases 0.000 description 3
- 108010016626 Dipeptides Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 230000037387 scars Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 description 2
- PLDLPVSQYMQDBL-UHFFFAOYSA-N 2-[[3-(oxiran-2-ylmethoxy)-2,2-bis(oxiran-2-ylmethoxymethyl)propoxy]methyl]oxirane Chemical compound C1OC1COCC(COCC1OC1)(COCC1OC1)COCC1CO1 PLDLPVSQYMQDBL-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010013296 Sericins Proteins 0.000 description 2
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- VYLDEYYOISNGST-UHFFFAOYSA-N bissulfosuccinimidyl suberate Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O VYLDEYYOISNGST-UHFFFAOYSA-N 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 239000007863 gel particle Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000005226 mechanical processes and functions Effects 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- LFKLPJRVSHJZPL-UHFFFAOYSA-N 1,2:7,8-diepoxyoctane Chemical compound C1OC1CCCCC1CO1 LFKLPJRVSHJZPL-UHFFFAOYSA-N 0.000 description 1
- PGMKGZOHRBZSSQ-UHFFFAOYSA-N 2-[2-(oxiran-2-ylmethoxy)ethenoxymethyl]oxirane Chemical group C1OC1COC=COCC1CO1 PGMKGZOHRBZSSQ-UHFFFAOYSA-N 0.000 description 1
- XOBTWQWSFMZPNQ-UHFFFAOYSA-N 5-(oxiran-2-ylmethyl)-7-oxabicyclo[4.1.0]heptane Chemical compound C1CCC2OC2C1CC1CO1 XOBTWQWSFMZPNQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 229920000896 Ethulose Polymers 0.000 description 1
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710137377 Sericin-2 Proteins 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical group O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229920003064 carboxyethyl cellulose Polymers 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 230000007691 collagen metabolic process Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical class C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002435 rhinoplasty Methods 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940075562 sodium phosphate dihydrate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- CRKADHVTAQCXRA-UHFFFAOYSA-K trisodium;phosphate;dihydrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]P([O-])([O-])=O CRKADHVTAQCXRA-UHFFFAOYSA-K 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
Definitions
- the present invention relates to a dermo-cosmetic composition with combined filling and regenerative effect on skin.
- the present invention origins in the cosmetic and aesthetic fields.
- the present invention relates to a dermo-cosmetic composition with filler and regenerative effect on the skin, comprising the combination of a two- components dermal filler with amino acid components having biological activity on the skin.
- Human skin aging is a multifactorial, complex and chronic biological process affecting the main skin components.
- the exposure of the skin to external factors such as solar radiation, heat or cold temperatures contributes to accelerate the aging of the skin.
- Skin aging especially in the face of an individual manifests with a thinning of the epidermis and a loss of elasticity and with the appearance of wrinkles, furrows, atrophy, relaxation and loss of skin elasticity.
- preparations containing substances with moisturizing, emollient and regenerating action are commonly used to improve the skin appearance and remedy to the signs of skin aging.
- Fillers are generally polymeric products injectable subcutaneously in the vicinity of wrinkles, skin furrows and in general in areas of the body where there is a sagging skin.
- the fillers available on the market can be divided into two main categories, those based on biodegradable substances and those non-biodegradable.
- Non-biodegradable fillers are called permanent fillers because they are not absorbable and are generally encapsulated in fibrous tissues and are not subject to hydrolysis or phagocytosis. While exerting a prolonged action, however, permanent fillers have a higher risk of developing allergic and rejection reactions by the human body.
- Typical examples of permanent fillers include liquid silicones, silicone particles in suspension, particles of acrylic hydrogel crosslinked with hyaluronic acid, calcium hydroxyapatite, polymethylmethacrylate microspheres dispersed in collagen and formulations of polyacrylamide gel.
- Biodegradable fillers are called temporary because their effect wears off over time and their application needs to be renewed to maintain unchanged the filling effect.
- Biodegradable fillers are generally divided into two types, the intermediate duration ones and the long duration ones.
- the intermediate duration ones are absorbable after a few months of implantation and are made of materials subject to degradation by enzymatic hydrolysis, such as hyaluronic acid, and therefore they gradually lose the initial ability to fill and relax the tissues.
- these polymers are biodegradable materials present in nature, with high biocompatibility and affinity with water.
- biodegradable polymer matrix have been modified so as to obtain polymers in crosslinked form with longer duration of action.
- hyaluronic acids are available on the market which are treated with crosslinking agents so as to form covalent bonds which make the resulting polymer matrix less subject to enzymatic hydrolysis and enzymatic degradation, once injected into the tissues.
- crosslinked polymer matrices are less soluble and less prone to degradation, they behave as inert substances that play a mere tissue filling function, without making a contribution to improve the conditions of the tissues that have led to the formation or accelerated the formation of the wrinkle.
- Some long duration of action fillers are also known which are made in synthetic polymer matrices. While having the advantage of being little biodegradable and thus having a long duration of action, these fillers are not free from drawbacks as they can cause allergic reactions or skin redness.
- One of the objects of the invention therefore is to provide a composition combining a filling effect with a biological effect on the skin.
- a further object is to provide a dermocosmetic filler that, when injected in the skin, is almost free of side effects.
- a further object of the invention is to provide an effective aesthetic or cosmetic method for the treatment of skin or photo-aging without using surgical treatments of the human body.
- the inventors found that the combination of a dermal filler component with a peptide component having biological activity provides a combined filling and regenerative effect on the skin.
- the invention provides a composition combining the filling properties typical of dermal fillers with the eutrophic and regenerative characteristics of peptides having biological and antiaging activity.
- the composition of the invention contains a two-component filler that fill in or plump body areas that have lost volume and smoothness combined with a biologically active peptide component.
- the present invention provides a composition comprising a filler component in combination with a peptide having biological and antiaging activity on the skin, wherein the filler component comprises a hyaluronic acid and a type 1 recombinant collagen protein.
- One of the two filler component is hyaluronic acid which may be in crosslinked or not crosslinked form.
- the other filler component is a recombinant collagen, especially a Recombinant type 1 Collagen protein.
- the cosmetic anti-aging components includes peptides having biological activity whose use improves the appearance of skin.
- the peptides having biological properties are dipeptides preferably selected from AlaPro, ProGly, GlyPro and mixtures thereof.
- the composition of the invention may also contain additional amino acids or peptides.
- the peptide having biological activity on the skin may be selected from AlaPro, ProGly, GlyPro and mixtures thereof.
- the peptide having biological activity on the skin stimulate the fibroblast activity combining the eutrophic and anti-aging action with the mechanical function of the filler component.
- composition of the invention finds application in the cosmetic and aesthetic field and in aesthetic medicine as well.
- the composition of the invention is a cosmetic composition designed to treat signs of skin aging and/or photo-aging in a human beings.
- composition may be used with the following indication of use: plump up thinning lips, enhance or fill in shallow areas on the face, decrease or remove the shadow or wrinkle under the eyes caused by the lower eyelid, fill in or soften the look of recessed scars, fill in or soften static wrinkles, especially on the lower face treat Static wrinkles which usually are a result of a loss of collagen and elasticity in the skin.
- the composition is a cosmetic composition suitable to treat or ameliorate the aspect of wrinkles especially around the mouth, thin lips, and cheeks.
- composition may also be used on forehead wrinkles, scars, and other areas that need extra volume for a smoother look.
- composition of the invention combines the mechanical function of a dermal filling with a cell regeneration activity and a delay in the skin aging process due to the sustained release of the peptides having biological activity to the tissues at the injection/implantation area.
- the combination of the fillers of the filling component increases the persistence time of the composition.
- the composition exerts a combined filling and cosmetic effect lasting from 2 to 14 months, from 3 to 10 months, from 4 to 6 months.
- composition of the invention may be applied on the skin or administered by intradermal or subcutaneous injection or implantation.
- the present invention provides a cosmetic method for treating skin aging and/or photo aging o comprising the injection of a cosmetically effective amount of a composition as defined herein.
- the cosmetic method of the invention stretches reduces, mitigates wrinkles, facial furrows, reshape, or fill the volumes of the skin.
- the present invention provides a method for ameliorating an aesthetic aspect of the skin and/or fill the volume of skin by applying on skin or injecting in the subcutaneous layer of skin an aesthetically effective amount of a composition according to anyone of the embodiments disclosed herein.
- Figs. 1 A and 1 B are photographic images made at times before (TO) and after 7 days (T7) from the skin treatment of a facial area of a female individual by intradermal injection of a composition having the formulation of Example 1 ;
- Fig. 2 shows a bluish area in 3D image elaboration of the facial area shown in previous Figs. 1 A, 1 B showing a reduction of nasolabial folds and an increase in the volume on and nearby the areas of treatment.
- the present invention originates from the finding that combining a dermal filler component with a biologically active peptide component, a synergistic cosmetic structural effect is achieved on the skin affected by skin aging, photo aging.
- the invention originates from the finding that the subcutaneous or intradermal injection of a composition combining a dermal component with mechanical and/or filler properties with a biologically active peptide component provides an effective and prolonged antiaging action on the skin.
- the prolongation of the antiaging action on the skin is due either to the extension of the filling effect and to the sustained release of the biologically active peptide component in the dermis where stimulates the production of collagen.
- the application onto skin or the injection in the skin of the dermo-cosmetic composition increase the volume of the treated area determining the skin stretching and relaxation and a reduction of the depth of the epidermal corrugations.
- the present invention provides either therapeutic or cosmetic uses of a composition as herein disclosed.
- the present invention therefore relates to a composition as defined in claim 1.
- Embodiments of the composition are defined in the appended dependent claims 2-7.
- composition defined in claim 1 as dermal filler or to increase the volume of a soft tissue, especially skin, is disclosed herein.
- the subcutaneous or intradermal injection of a cosmetically effective amount of the filler composition is provided.
- a component of the composition is hyaluronic acid (HA), a naturally occurring non sulfate linear polysaccharide comprising repeating disaccharide units of d- glucuronic acid and /V-acetyl-d-glucosamine linked by b-1 -3 and b-1 -4 glycosidic bonds.
- Hyaluronic acid is classified in three groups depending on its molecular weights: high molecular weight (HMWHA) is greater than 1 * 10 6 Da, low molecular weight (LMWHA) is from 0.8 to 8 c 10 5 Da, and oligo-HA is equal to or less than 6 c 10 3 Da.
- Hyaluronic acid is a primary component of the extracellular matrix of human connective tissues. It is also an important structural element in the skin.
- the hyaluronic acid of the composition may be in free form or as a salt in the form of a physiologically acceptable salt such as sodium or potassium hyaluronate.
- a suitable hyaluronic acid has a high molecular weight as defined above.
- a suitable not-crosslinked hyaluronic acid may have a molecular weight greater than 1.000.000 Da, from 1.200.000, to 8.000.000 Da, of 1.500.000 to 3.500.000 Dalton.
- the molecular weight of hyaluronic acid as described herein are weight average molecular weight MW, expressed in Dalton.
- the hyaluronic acid molecular weight may be determined using standard methods, for example as described by Ueno et al., 1988, Chem Pharm Bull. 36, 4971 -4975; Wyatt 1993, Anal Chim Acta 272: 1 -40; Watt Technologies 1999 “Light scattering University Dawn Course Manual and“Dawn Eos Manual” Wyatt Technology Corp. Santa Barbara CA (USA).
- the hyaluronic acid of the composition is at least partially cross-linked with a crosslinking agent.
- Suitable crosslinking agents include crosslinking agents based on dialdehydes and disulfides, PEG, diglycidyl ethers, bis-carbodiimides, bis-epoxides and mixtures thereof.
- crosslinks examples include polyethylene glycol diglycil ether, polyethylene glycol epoxide, divinyl sulfone (DVS), pentaerythritol tetraglycidyl ether (PETGE), 1 ,4-butanediol diglycidyl ether (BDDE), 1 ,2-bis(2,3-epoxypropoxy)ethylene (EDGE), 1 ,2,7,8-diepoxyoctane (DEO), phenylene-bis-(ethyl)-carbodiimide, 1 ,6- hexane-ethylene bis-(ethylcarbodiimide), adipic dihydrazide (ADH), bis(sulfosuccinimidyl)suberate (BS), hexamethylenediamine (HMDA), 1 -(2,3- epoxypropyl)-2, 3-epoxycyclohexane, BTDE or mixtures thereof.
- the hyaluronic acid of the composition may be in the form of a gel which may be spread on the skin or administered by subcutaneous injection.
- the hyaluronic acids of the invention have a crosslinking degree from 0.1 to 85%, from 1 to 50% 10 to 20% in relation to the molecular weight of the polymer.
- a component of the composition is a recombinant type 1 collagen especially recombinant type I collagen cd chain preferably produced by transgenic silkworms.
- said transgenic silkworms possess an expression cassette in its genome and expresses a recombinant protein such as recombinant type 1 collagen in its middle silk gland.
- the expression cassette comprises a polynucleotide having the SEQ ID NO: 1 or a part thereof as described on pages 13 and 14 of EP 1 81 1 027 B1 which typically is linked with a structural gene for the recombinant protein.
- the recombinant type 1 collagen used herein may be obtained by the method disclosed in the European Patent EP 1 81 1 027 B1 especially in par.
- the human recombinant type 1 collagen is obtained by a process for producing a recombinant protein comprising extracting the recombinant protein from cocoons of a transgenic silkworm which possesses (in its genome) an expression cassette for expressing the recombinant protein in silkworm middle silk gland and secrete the recombinant protein in the sericin layer of silk filaments.
- a suitable polynucleotide comprises a polynucleotide corresponding to a promoter region of sericin 1 gene or sericin 2 gene which is functionally linked with a polynucleotide corresponding to baculovirus homologous regions especially having the nucleotide sequence of SEQ ID NO: 1 or a part thereof as reported either in EP 1 81 1 027 or JP 2004301834.
- the composition of the invention contains recombinant type 1 collagen, especially human recombinant type 1 collagen, from 0,0001 to 5%, from 0,001 to 1 ,000% by weight
- the composition of the invention is a composition in a form suitable for the application by subcutaneous or intradermal injection or by implantation in a body area, especially face, of a human being.
- the composition of the invention contains from 0.01 to 80%, from 0.5 to 60%, from 1 to 50%, or from 10 to 40% by weight of HA. According to some embodiments, the composition of the invention contains from 0.001 to 20%, from 0.01 to 10%, from 0,5 to 4%, by weight of recombinant type 1 collagen.
- a further component of the composition is a dipeptides selected from AlaPro, ProGly, GlyPro and mixtures thereof.
- the mixture of the three dipeptides is preferred to achieve a combined filler and regenerative effect on the skin.
- the composition may also contains biologically active amino acid or peptide performing a function in skin care and selected from Alanine, Valine, Glycine, Proline, OH-Proline, Aspartic acid, Lisine, Glutamic Acid, Glutamine, Asparagine, Leucine and mixtures thereof.
- biologically active amino acid or peptide performing a function in skin care and selected from Alanine, Valine, Glycine, Proline, OH-Proline, Aspartic acid, Lisine, Glutamic Acid, Glutamine, Asparagine, Leucine and mixtures thereof.
- the amino acids Alanine, Valine, Glycine, Proline, OH-Proline, lysine are L- isomers.
- the amino acids or peptides have a biological activity on the skin, especially on skin collagen metabolism and improve the collagen synthesis rate.
- the amino acids of the composition maintain the skin’s hydration in physiological conditions, strength the immune system thus providing an overall healthy appearance to the skin. They amino acid also protect skin from free-radical damage and activates the physiological trophism of skin thus reducing the signs of ageing.
- the above biologically active amino acids and/or peptides activate the fibroblasts and are active on the intracellular components of the skin thus improving the aesthetic aspect of the skin.
- This cosmetic effect on the skin is complementary to the main filling effects exerted by the filling components of the composition.
- the composition may contain a physiologically acceptable excipient or carrier.
- the physiologically acceptable carrier of the composition of the invention is an excipient, carrier or diluent suitable for intradermal or intracutaneous/intradermal administration or topical application.
- a suitable carrier may be water for the subcutaneous or intradermal.
- Suitable carriers in liquid form include water, preferably ultrapure or for pharmaceutical use, isotonic saline solution (0.9%), aqueous solutions with phosphate buffer (PBS), Ringer's solutions, or aqueous solutions containing one or more of carbonate, citrate, acetate, glycine and mixtures thereof.
- isotonic saline solution 0.8%
- aqueous solutions with phosphate buffer (PBS) phosphate buffer
- Ringer's solutions or aqueous solutions containing one or more of carbonate, citrate, acetate, glycine and mixtures thereof.
- the composition of the invention contains one or more pH regulating agents and/or buffer systems of the conventional type in the techniques of preparation of injectable pharmaceutical solutions.
- phosphate or tartrate buffers may be used to adjust the pH to physiologically compatible values.
- the composition contains a NaOH solution to have a pH from 4.5 to 8, from 6 to 7.6.
- composition of the invention in injectable form is a sterile and pyrogen-free saline.
- the composition of the invention is in the form of gel or hydrogel suitable for subcutaneous or intradermal injection.
- the gel or hydrogel particles have a particle size equal to or less than 700 pm. For example, from 50 to 700 pm, or from 100 to 400 pm, or from 200 to 300 pm, measured as the mass median diameter by laser diffraction technique or by microscopic analysis.
- the monophasic gel is almost free from gel particles.
- the composition of the invention is in the form of a water-based suspension.
- the composition of the invention further comprises one or more physiologically acceptable excipients such as antioxidants, diluents, solvents, preservatives, bactericidal agents, stabilizers, emulsifiers, surfactants, buffers, humectants, dyes, or other excipients commonly used in cosmetic/pharmaceutical preparation techniques.
- physiologically acceptable excipients such as antioxidants, diluents, solvents, preservatives, bactericidal agents, stabilizers, emulsifiers, surfactants, buffers, humectants, dyes, or other excipients commonly used in cosmetic/pharmaceutical preparation techniques.
- Suitable excipients are sodium chloride, sodium phosphate monobasic and or dibasic, cellulose and its derivatives such as carboxymethylcellulose. hydroxymethylcellulose, hydroxypropyl methylcellulose, methylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, carboxyethylcellulose, ethylhydroxyethylcellulose, carboxymethylcellulose, cellulose acetate butyrate, cellulose acetate phthalate, and mixtures thereof.
- composition of the invention may further contain one or more antioxidants such sodium bisulfite, glutathione, coenzyme Q and mixtures thereof or vitamins such as vitamin B6, vitamin C.
- antioxidants such as sodium bisulfite, glutathione, coenzyme Q and mixtures thereof or vitamins such as vitamin B6, vitamin C.
- the composition of the invention comprises further cosmetically active substances which can be administered by injection.
- a cosmetic or aesthetic treatment method comprises application of a cosmetically acceptable amount of a composition as defined herein.
- the cosmetic or aesthetic treatment method of the invention may be applied in the treatment of any area of the body, such as the face, the lips, the area around the eyes, breasts, buttocks, and in particular to improve the aesthetic quality of a anatomical feature.
- the composition of the invention is suitable for use for aesthetic purposes, in particular to increase the volume of areas of the body, for example the lips, around the eyes, or in the treatment, prevention, distension of wrinkles, skin folds or corrugations, particularly those located on the face.
- the cosmetic treatment method involves the intradermal or subcutaneous injection of a composition according to any one of the embodiments previously described for filling wrinkles, facial corrugations, skin depressions or scars.
- the composition of the invention may contain a local anesthetic, such as lidocaine, tetracaine, mepivacaine, procaine, benzocaine, and mixtures thereof, analgesics such as non-steroidal anti-inflammatory drugs, antimicrobials such as antibiotics for local use and mixtures thereof.
- a local anesthetic such as lidocaine, tetracaine, mepivacaine, procaine, benzocaine, and mixtures thereof
- analgesics such as non-steroidal anti-inflammatory drugs, antimicrobials such as antibiotics for local use and mixtures thereof.
- the active principles contained in the composition of the present invention can be combined or mixed as active principles in intimate admixture with a suitable carrier and/or excipient according to pharmaceutical techniques.
- the filler or the filler composition of the invention can be applied in the field of aesthetic medicine.
- the filler or the composition of the invention are applied in reconstructive surgery, such as in maxillofacial or aesthetic surgery, for example in plastic surgery or conservative aesthetics, for example in blepharoplasty or rhinoplasty.
- the filler or the filler composition of the invention can be applied in cosmetic and/or aesthetic filed.
- a method for the treatment of an area of the body of an individual for aesthetic purposes comprising the application or administration to an individual of a filler or of a composition comprising a filler according to the invention.
- carrier refers to an excipient, carrier, diluent or adjuvant which may be present in the composition of the invention. Any carrier and/or excipient suitable for the desired form of preparation for administration is envisaged in the uses described herein.
- compositions or components thereof are suitable for cosmetic use and when applied, do not cause toxicity, allergic response, redness, incompatibility, instability and similar undesired reactions.
- physiologically acceptable means that the substance, when applied or administered to the human body, does not cause toxicity, allergic response, redness, incompatibility, instability and similar undesired reactions.
- crosslinked refers to intermolecular bonds that bind molecules or individual polymer chains such as HA or monomeric moieties thereof in a more stable structure.
- the term "monophasic gel” means a network of crosslinked viscoelastic gel comprising less than 20%, less than 10%, less than 5% by weight of gel particles.
- biocompatible means a product or products that are physiologically acceptable and that when injected do not cause significant adverse reactions or anyway if they occur, they are of local type and are among the reactions and discomfort commonly encountered upon injection or implantation of products of known use.
- composition having the following formulation The above composition is obtained by a process including the following steps:
- Example 1 The individual was treated by intradermal (subcutaneous) injection of a composition having the formulation of Example 1.
- the intradermal injection was performed at time TO (baseline) during the basal visit, after evaluations planned by the study procedure, in the malar area (zygomatic protuberance), by bolus technique using a needle.
- a cannula for aesthetic uses may be used for injecting the composition
- the amount of tested product injected was determined by the investigator for each subject in 3 ml. This dosage may be varied from 2 to 5 ml.
- the efficacy of the cosmetic effect was evaluated in a visit made 7 days (T7) after the day of the treatment.
Abstract
The present invention, in one aspect, relates to a dermo-cosmetic composition having filler and regenerative effect on the skin, comprising the combination of a two-component dermal filler with a peptide component having biological activity on the skin.
Description
"Cosmetic composition with combined filler and skin regenerative effect"
DESCRIPTION FIELD OF THE INVENTION
The present invention relates to a dermo-cosmetic composition with combined filling and regenerative effect on skin.
The present invention origins in the cosmetic and aesthetic fields.
In particular, the present invention relates to a dermo-cosmetic composition with filler and regenerative effect on the skin, comprising the combination of a two- components dermal filler with amino acid components having biological activity on the skin.
PRIOR ART
Human skin aging is a multifactorial, complex and chronic biological process affecting the main skin components.
Even if the skin aging mechanism is not yet fully know, recent studies have shown that the skin tends to lose the molecules responsible for binding and retaining water molecules while a reduction in the number and functionality of fibroblasts and collagen occurs.
The exposure of the skin to external factors such as solar radiation, heat or cold temperatures contributes to accelerate the aging of the skin.
Skin aging especially in the face of an individual manifests with a thinning of the epidermis and a loss of elasticity and with the appearance of wrinkles, furrows, atrophy, relaxation and loss of skin elasticity.
In the cosmetic field, preparations containing substances with moisturizing, emollient and regenerating action are commonly used to improve the skin appearance and remedy to the signs of skin aging.
However, the cosmetic effects resulting from the topical applications of these cosmetic substances is not considered fully satisfactory by the users.
For this reasons, certain techniques providing for the intradermal injection of dermo-cosmetic fillers have been developed in alternative to the topical application of cosmetic substances.
In aesthetic medicine, the dermal fillers are used to treat these signs of aging and to fill skin wrinkles or increase volumes.
Fillers are generally polymeric products injectable subcutaneously in the vicinity of wrinkles, skin furrows and in general in areas of the body where there is a sagging skin.
Once injected, they mainly carry out a mechanical action of filling the tissues, causing an action of stretching and relaxation of the skin which reduces the depth of the epidermal furrows.
The fillers available on the market can be divided into two main categories, those based on biodegradable substances and those non-biodegradable.
Non-biodegradable fillers are called permanent fillers because they are not absorbable and are generally encapsulated in fibrous tissues and are not subject to hydrolysis or phagocytosis. While exerting a prolonged action, however, permanent fillers have a higher risk of developing allergic and rejection reactions by the human body.
Typical examples of permanent fillers include liquid silicones, silicone particles in suspension, particles of acrylic hydrogel crosslinked with hyaluronic acid, calcium hydroxyapatite, polymethylmethacrylate microspheres dispersed in collagen and formulations of polyacrylamide gel.
Biodegradable fillers are called temporary because their effect wears off over time and their application needs to be renewed to maintain unchanged the filling effect. Biodegradable fillers are generally divided into two types, the intermediate duration ones and the long duration ones. The intermediate duration ones are absorbable after a few months of implantation and are made of materials subject to degradation by enzymatic hydrolysis, such as hyaluronic acid, and therefore they gradually lose the initial ability to fill and relax the tissues. Typically these polymers are biodegradable materials present in nature, with high biocompatibility and affinity with water.
However, these polymeric matrices, such as hyaluronic acid, are rapidly hydrolysed once implanted in a tissue, and the results obtained, although appreciable from an aesthetic point of view, do not last long.
In order to remedy these problems, the biodegradable polymer matrix have been
modified so as to obtain polymers in crosslinked form with longer duration of action.
At present, hyaluronic acids are available on the market which are treated with crosslinking agents so as to form covalent bonds which make the resulting polymer matrix less subject to enzymatic hydrolysis and enzymatic degradation, once injected into the tissues.
Because these crosslinked polymer matrices are less soluble and less prone to degradation, they behave as inert substances that play a mere tissue filling function, without making a contribution to improve the conditions of the tissues that have led to the formation or accelerated the formation of the wrinkle.
Some long duration of action fillers are also known which are made in synthetic polymer matrices. While having the advantage of being little biodegradable and thus having a long duration of action, these fillers are not free from drawbacks as they can cause allergic reactions or skin redness.
At present, there is still a demand for cosmetic products having an effective filling action combined with cosmetic properties.
One of the objects of the invention therefore is to provide a composition combining a filling effect with a biological effect on the skin.
A further object is to provide a dermocosmetic filler that, when injected in the skin, is almost free of side effects.
A further object of the invention is to provide an effective aesthetic or cosmetic method for the treatment of skin or photo-aging without using surgical treatments of the human body.
SUMMARY OF THE INVENTION
The inventors, in accordance with an aspect of the invention, found that the combination of a dermal filler component with a peptide component having biological activity provides a combined filling and regenerative effect on the skin.
In one aspect, the invention provides a composition combining the filling properties typical of dermal fillers with the eutrophic and regenerative characteristics of peptides having biological and antiaging activity.
Typically, the composition of the invention contains a two-component filler that fill in or plump body areas that have lost volume and smoothness combined with a
biologically active peptide component.
In accordance with a first aspect, the present invention provides a composition comprising a filler component in combination with a peptide having biological and antiaging activity on the skin, wherein the filler component comprises a hyaluronic acid and a type 1 recombinant collagen protein.
One of the two filler component is hyaluronic acid which may be in crosslinked or not crosslinked form.
The other filler component is a recombinant collagen, especially a Recombinant type 1 Collagen protein.
The cosmetic anti-aging components includes peptides having biological activity whose use improves the appearance of skin.
Typically, the peptides having biological properties are dipeptides preferably selected from AlaPro, ProGly, GlyPro and mixtures thereof. The composition of the invention may also contain additional amino acids or peptides.
The peptide having biological activity on the skin may be selected from AlaPro, ProGly, GlyPro and mixtures thereof.
Typically, the peptide having biological activity on the skin stimulate the fibroblast activity combining the eutrophic and anti-aging action with the mechanical function of the filler component.
The composition of the invention finds application in the cosmetic and aesthetic field and in aesthetic medicine as well.
Typically, the composition of the invention is a cosmetic composition designed to treat signs of skin aging and/or photo-aging in a human beings.
The composition may be used with the following indication of use: plump up thinning lips, enhance or fill in shallow areas on the face, decrease or remove the shadow or wrinkle under the eyes caused by the lower eyelid, fill in or soften the look of recessed scars, fill in or soften static wrinkles, especially on the lower face treat Static wrinkles which usually are a result of a loss of collagen and elasticity in the skin.
Typically, the composition is a cosmetic composition suitable to treat or ameliorate the aspect of wrinkles especially around the mouth, thin lips, and cheeks.
The composition may also be used on forehead wrinkles, scars, and other areas
that need extra volume for a smoother look.
The composition of the invention combines the mechanical function of a dermal filling with a cell regeneration activity and a delay in the skin aging process due to the sustained release of the peptides having biological activity to the tissues at the injection/implantation area.
Moreover, the combination of the fillers of the filling component increases the persistence time of the composition. For example, the composition exerts a combined filling and cosmetic effect lasting from 2 to 14 months, from 3 to 10 months, from 4 to 6 months.
Typically, the composition of the invention may be applied on the skin or administered by intradermal or subcutaneous injection or implantation.
According to an aspect, the present invention provides a cosmetic method for treating skin aging and/or photo aging o comprising the injection of a cosmetically effective amount of a composition as defined herein.
According to certain embodiments, the cosmetic method of the invention stretches reduces, mitigates wrinkles, facial furrows, reshape, or fill the volumes of the skin. In accordance with another aspect, the present invention provides a method for ameliorating an aesthetic aspect of the skin and/or fill the volume of skin by applying on skin or injecting in the subcutaneous layer of skin an aesthetically effective amount of a composition according to anyone of the embodiments disclosed herein.
The present invention is described in details herein below by making reference to the enclosed figures.
BRIEF DESCRIPTION OF THE DRAWINGS
Some features and advantages of the present invention will become apparent from the accompanying drawings, in which:
Figs. 1 A and 1 B are photographic images made at times before (TO) and after 7 days (T7) from the skin treatment of a facial area of a female individual by intradermal injection of a composition having the formulation of Example 1 ;
Fig. 2 shows a bluish area in 3D image elaboration of the facial area shown in previous Figs. 1 A, 1 B showing a reduction of nasolabial folds and an increase in the volume on and nearby the areas of treatment.
DETAILED DESCRIPTION OF THE INVENTION
The present invention originates from the finding that combining a dermal filler component with a biologically active peptide component, a synergistic cosmetic structural effect is achieved on the skin affected by skin aging, photo aging.
In particular, the invention originates from the finding that the subcutaneous or intradermal injection of a composition combining a dermal component with mechanical and/or filler properties with a biologically active peptide component provides an effective and prolonged antiaging action on the skin.
The prolongation of the antiaging action on the skin is due either to the extension of the filling effect and to the sustained release of the biologically active peptide component in the dermis where stimulates the production of collagen.
The application onto skin or the injection in the skin of the dermo-cosmetic composition increase the volume of the treated area determining the skin stretching and relaxation and a reduction of the depth of the epidermal corrugations.
The present invention provides either therapeutic or cosmetic uses of a composition as herein disclosed.
According to a first aspect thereof, the present invention therefore relates to a composition as defined in claim 1. Embodiments of the composition are defined in the appended dependent claims 2-7.
In another aspect, the use of a composition defined in claim 1 as dermal filler or to increase the volume of a soft tissue, especially skin, is disclosed herein.
Typically, for this use, the subcutaneous or intradermal injection of a cosmetically effective amount of the filler composition is provided.
A component of the composition is hyaluronic acid (HA), a naturally occurring non sulfate linear polysaccharide comprising repeating disaccharide units of d- glucuronic acid and /V-acetyl-d-glucosamine linked by b-1 -3 and b-1 -4 glycosidic bonds. Hyaluronic acid is classified in three groups depending on its molecular weights: high molecular weight (HMWHA) is greater than 1 * 106 Da, low molecular weight (LMWHA) is from 0.8 to 8 c 105 Da, and oligo-HA is equal to or less than 6 c 103 Da.
Hyaluronic acid is a primary component of the extracellular matrix of human
connective tissues. It is also an important structural element in the skin.
The hyaluronic acid of the composition may be in free form or as a salt in the form of a physiologically acceptable salt such as sodium or potassium hyaluronate.
A suitable hyaluronic acid has a high molecular weight as defined above. For example, a suitable not-crosslinked hyaluronic acid may have a molecular weight greater than 1.000.000 Da, from 1.200.000, to 8.000.000 Da, of 1.500.000 to 3.500.000 Dalton.
Typically, the molecular weight of hyaluronic acid as described herein are weight average molecular weight MW, expressed in Dalton.
The hyaluronic acid molecular weight may be determined using standard methods, for example as described by Ueno et al., 1988, Chem Pharm Bull. 36, 4971 -4975; Wyatt 1993, Anal Chim Acta 272: 1 -40; Watt Technologies 1999 “Light scattering University Dawn Course Manual and“Dawn Eos Manual” Wyatt Technology Corp. Santa Barbara CA (USA).
In certain embodiments, the hyaluronic acid of the composition is at least partially cross-linked with a crosslinking agent. Suitable crosslinking agents include crosslinking agents based on dialdehydes and disulfides, PEG, diglycidyl ethers, bis-carbodiimides, bis-epoxides and mixtures thereof.
Examples of crosslinks include polyethylene glycol diglycil ether, polyethylene glycol epoxide, divinyl sulfone (DVS), pentaerythritol tetraglycidyl ether (PETGE), 1 ,4-butanediol diglycidyl ether (BDDE), 1 ,2-bis(2,3-epoxypropoxy)ethylene (EDGE), 1 ,2,7,8-diepoxyoctane (DEO), phenylene-bis-(ethyl)-carbodiimide, 1 ,6- hexane-ethylene bis-(ethylcarbodiimide), adipic dihydrazide (ADH), bis(sulfosuccinimidyl)suberate (BS), hexamethylenediamine (HMDA), 1 -(2,3- epoxypropyl)-2, 3-epoxycyclohexane, BTDE or mixtures thereof.
The hyaluronic acid of the composition may be in the form of a gel which may be spread on the skin or administered by subcutaneous injection.
According to some embodiments, the hyaluronic acids of the invention have a crosslinking degree from 0.1 to 85%, from 1 to 50% 10 to 20% in relation to the molecular weight of the polymer.
A component of the composition is a recombinant type 1 collagen especially recombinant type I collagen cd chain preferably produced by transgenic
silkworms. Preferably, said transgenic silkworms possess an expression cassette in its genome and expresses a recombinant protein such as recombinant type 1 collagen in its middle silk gland. The expression cassette comprises a polynucleotide having the SEQ ID NO: 1 or a part thereof as described on pages 13 and 14 of EP 1 81 1 027 B1 which typically is linked with a structural gene for the recombinant protein.
Typically, the recombinant type 1 collagen used herein may be obtained by the method disclosed in the European Patent EP 1 81 1 027 B1 especially in par.
[0031 ], [0032] or claims 16 and 17, or in its priority application JP 2004301834 filed on 15 October 2004, especially as disclosed under par. 0040.
For example, the human recombinant type 1 collagen is obtained by a process for producing a recombinant protein comprising extracting the recombinant protein from cocoons of a transgenic silkworm which possesses (in its genome) an expression cassette for expressing the recombinant protein in silkworm middle silk gland and secrete the recombinant protein in the sericin layer of silk filaments. A suitable polynucleotide comprises a polynucleotide corresponding to a promoter region of sericin 1 gene or sericin 2 gene which is functionally linked with a polynucleotide corresponding to baculovirus homologous regions especially having the nucleotide sequence of SEQ ID NO: 1 or a part thereof as reported either in EP 1 81 1 027 or JP 2004301834.
According to some embodiments, the composition of the invention contains recombinant type 1 collagen, especially human recombinant type 1 collagen, from 0,0001 to 5%, from 0,001 to 1 ,000% by weight
Typically, the composition of the invention is a composition in a form suitable for the application by subcutaneous or intradermal injection or by implantation in a body area, especially face, of a human being.
According to some embodiments, the composition of the invention contains from 0.01 to 80%, from 0.5 to 60%, from 1 to 50%, or from 10 to 40% by weight of HA. According to some embodiments, the composition of the invention contains from 0.001 to 20%, from 0.01 to 10%, from 0,5 to 4%, by weight of recombinant type 1 collagen.
A further component of the composition is a dipeptides selected from AlaPro,
ProGly, GlyPro and mixtures thereof. The mixture of the three dipeptides is preferred to achieve a combined filler and regenerative effect on the skin.
Typically, the composition may also contains biologically active amino acid or peptide performing a function in skin care and selected from Alanine, Valine, Glycine, Proline, OH-Proline, Aspartic acid, Lisine, Glutamic Acid, Glutamine, Asparagine, Leucine and mixtures thereof. Preferably, the amino acids Alanine, Valine, Glycine, Proline, OH-Proline, lysine are L- isomers.
Advantageously, the amino acids or peptides have a biological activity on the skin, especially on skin collagen metabolism and improve the collagen synthesis rate. The amino acids of the composition maintain the skin’s hydration in physiological conditions, strength the immune system thus providing an overall healthy appearance to the skin. They amino acid also protect skin from free-radical damage and activates the physiological trophism of skin thus reducing the signs of ageing.
The above biologically active amino acids and/or peptides activate the fibroblasts and are active on the intracellular components of the skin thus improving the aesthetic aspect of the skin. This cosmetic effect on the skin is complementary to the main filling effects exerted by the filling components of the composition.
In accordance with an embodiment the composition combines cosmetically effective amounts of
i) a filler component of hyaluronic acid and recombinant type 1 collagen with ii) biologically active peptides AlaPro, ProGly, GlyPro.
The composition may contain a physiologically acceptable excipient or carrier. Typically, the physiologically acceptable carrier of the composition of the invention is an excipient, carrier or diluent suitable for intradermal or intracutaneous/intradermal administration or topical application. A suitable carrier may be water for the subcutaneous or intradermal.
Suitable carriers in liquid form include water, preferably ultrapure or for pharmaceutical use, isotonic saline solution (0.9%), aqueous solutions with phosphate buffer (PBS), Ringer's solutions, or aqueous solutions containing one or more of carbonate, citrate, acetate, glycine and mixtures thereof.
According to some embodiments, the composition of the invention contains one or
more pH regulating agents and/or buffer systems of the conventional type in the techniques of preparation of injectable pharmaceutical solutions.
For example, phosphate or tartrate buffers may be used to adjust the pH to physiologically compatible values.
In certain embodiments the composition contains a NaOH solution to have a pH from 4.5 to 8, from 6 to 7.6.
Typically, the composition of the invention in injectable form is a sterile and pyrogen-free saline.
According to some embodiments, the composition of the invention is in the form of gel or hydrogel suitable for subcutaneous or intradermal injection.
In some embodiments, the gel or hydrogel particles have a particle size equal to or less than 700 pm. For example, from 50 to 700 pm, or from 100 to 400 pm, or from 200 to 300 pm, measured as the mass median diameter by laser diffraction technique or by microscopic analysis.
According to other embodiments, the monophasic gel is almost free from gel particles.
According to some embodiments, the composition of the invention is in the form of a water-based suspension.
According to some embodiments, the composition of the invention further comprises one or more physiologically acceptable excipients such as antioxidants, diluents, solvents, preservatives, bactericidal agents, stabilizers, emulsifiers, surfactants, buffers, humectants, dyes, or other excipients commonly used in cosmetic/pharmaceutical preparation techniques.
Suitable excipients are sodium chloride, sodium phosphate monobasic and or dibasic, cellulose and its derivatives such as carboxymethylcellulose. hydroxymethylcellulose, hydroxypropyl methylcellulose, methylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, carboxyethylcellulose, ethylhydroxyethylcellulose, carboxymethylcellulose, cellulose acetate butyrate, cellulose acetate phthalate, and mixtures thereof.
The composition of the invention may further contain one or more antioxidants such sodium bisulfite, glutathione, coenzyme Q and mixtures thereof or vitamins such as vitamin B6, vitamin C.
In some embodiments, the composition of the invention comprises further cosmetically active substances which can be administered by injection.
In accordance with an aspect of the invention, a cosmetic or aesthetic treatment method is provided that comprises application of a cosmetically acceptable amount of a composition as defined herein.
The cosmetic or aesthetic treatment method of the invention may be applied in the treatment of any area of the body, such as the face, the lips, the area around the eyes, breasts, buttocks, and in particular to improve the aesthetic quality of a anatomical feature.
According to certain embodiments, the composition of the invention is suitable for use for aesthetic purposes, in particular to increase the volume of areas of the body, for example the lips, around the eyes, or in the treatment, prevention, distension of wrinkles, skin folds or corrugations, particularly those located on the face.
In some embodiments, the cosmetic treatment method involves the intradermal or subcutaneous injection of a composition according to any one of the embodiments previously described for filling wrinkles, facial corrugations, skin depressions or scars.
In certain embodiments, the composition of the invention may contain a local anesthetic, such as lidocaine, tetracaine, mepivacaine, procaine, benzocaine, and mixtures thereof, analgesics such as non-steroidal anti-inflammatory drugs, antimicrobials such as antibiotics for local use and mixtures thereof.
In some embodiments, the active principles contained in the composition of the present invention can be combined or mixed as active principles in intimate admixture with a suitable carrier and/or excipient according to pharmaceutical techniques.
According to some aspects of the present invention, the filler or the filler composition of the invention can be applied in the field of aesthetic medicine.
In some embodiments, the filler or the composition of the invention are applied in reconstructive surgery, such as in maxillofacial or aesthetic surgery, for example in plastic surgery or conservative aesthetics, for example in blepharoplasty or rhinoplasty.
In accordance with other aspects of the present invention, the filler or the filler composition of the invention can be applied in cosmetic and/or aesthetic filed.
In accordance with an aspect of the invention, a method for the treatment of an area of the body of an individual for aesthetic purposes is provided comprising the application or administration to an individual of a filler or of a composition comprising a filler according to the invention.
Definitions
In the present document, the term "carrier" refers to an excipient, carrier, diluent or adjuvant which may be present in the composition of the invention. Any carrier and/or excipient suitable for the desired form of preparation for administration is envisaged in the uses described herein.
The term "cosmetically acceptable" as used herein means that the composition or components thereof are suitable for cosmetic use and when applied, do not cause toxicity, allergic response, redness, incompatibility, instability and similar undesired reactions.
The term "physiologically acceptable" means that the substance, when applied or administered to the human body, does not cause toxicity, allergic response, redness, incompatibility, instability and similar undesired reactions.
In general, the term "crosslinked" refers to intermolecular bonds that bind molecules or individual polymer chains such as HA or monomeric moieties thereof in a more stable structure.
Within the scope of invention, the term "monophasic gel" means a network of crosslinked viscoelastic gel comprising less than 20%, less than 10%, less than 5% by weight of gel particles.
The term biocompatible means a product or products that are physiologically acceptable and that when injected do not cause significant adverse reactions or anyway if they occur, they are of local type and are among the reactions and discomfort commonly encountered upon injection or implantation of products of known use.
The following examples are provided to illustrate the present invention.
EXAMPLE 1
Cosmetic composition having the following formulation
EXAMPLE 2
Composition having the following formulation
The above composition is obtained by a process including the following steps:
1 ) weigh the ppi water needed.
2) add under stirring, respectively: Sodium Chloride, Biphasic Sodium Phoshate Dodecahydrate, Monophasic Sodium Phosphate Dihydrate. Let dissolve.
3) once dissolved, add all the amino acids in the same order of the formula.
4) dissolve the amino acids and bring the pH in a range from 6,5 to 7,5. Bring the pH around 7,10
5) add the Vitamin B and let dissolve
6) add powdered Sodium Hyaluronate LW, as defined above, till complete dispersion
7) add recombinant Collagen till dispersion
8) add sodium Carboxymethylcellulose till dispersion and swelling overnight. EXAMPLE 3
Composition with the following formulation
EXAMPLE 4
Experimental evidence of the cosmetic effect of the combined composition.
An open, clinical trial was performed on an individual of female gender of 60 years. The individual was affected by wrinkles on the face.
Two visits were performed: basal and 1 week after the injection.
The individual was treated by intradermal (subcutaneous) injection of a composition having the formulation of Example 1.
The intradermal injection was performed at time TO (baseline) during the basal visit, after evaluations planned by the study procedure, in the malar area (zygomatic protuberance), by bolus technique using a needle. In the alternative, a cannula for aesthetic uses may be used for injecting the composition
The amount of tested product injected, was determined by the investigator for each subject in 3 ml. This dosage may be varied from 2 to 5 ml.
The efficacy of the cosmetic effect was evaluated in a visit made 7 days (T7) after the day of the treatment.
As can be seen in comparative Figures 1 and 2, after 7 days (T7) from the day TO (baseline) of the cosmetic treatment, nasolabial folds were reduced and cheek volume increased (bluish area in 3D image elaboration). This outcome was confirmed by 3D image elaboration of the face of the individual made before and 7 days after the cosmetic treatment, as illustrated in Fig. 2.
Claims
1. A composition comprising a dermal filler component in combination with a peptide and/or amino acid having biological and antiaging activity on the skin, wherein the filler component comprises a hyaluronic acid or a salt thereof and a recombinant type 1 collagen protein.
2. The composition of claim 1 wherein the peptide is selected from AlaPro, ProGly, GlyPro and mixtures thereof.
3. The composition of claim 1 or 2 wherein the peptides are AlaPro, ProGly and GlyPro.
4. The composition according to anyone of claims 1 -3 further comprising an amino acid selected from Alanine, Valine, Glycine, Proline, OH-Proline, Lisine, Glutamic Acid, Glutamine, Asparagine, Leucine and mixtures thereof.
5. The composition according to anyone of claims 1 -3 comprising the amino acid Alanine, Valine, Glycine, Aspartic acid, Proline, OH-Proline, Lisine, Glutamic Acid, Glutamine, Asparagine, Leucine.
6. The composition according to anyone of claims 1 -5 wherein the recombinant type 1 collagen is produced by transgenic silkworms.
7. The composition according to anyone of claim 1 -6 wherein the hyaluronic acid is a low molecular weight from 0.8 to 8 c 105 Da.
8. Cosmetic use of a composition according to anyone of claims 1 -7 for improving an aesthetic aspect of an individual.
9. Cosmetic use according to claim 8 for increasing the volume or reshaping a soft tissue, especially skin of the face or neck.
10. Cosmetic use according to claim 8 for reducing the depth or ameliorating the aesthetic aspect of wrinkles, folds, corrugations, furrows, folds, in particular on the face or neck.
1 1.Composition comprising a dermal filler component in combination with a peptide and/or amino acid having biological and antiaging activity on the skin, wherein the filler component comprises a hyaluronic acid or a salt thereof and a recombinant type 1 collagen protein for use in the treatment of wrinkles, folds, corrugations, furrows, folds by a subcutaneous injection
of a cosmetically active amount of said composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22152960.5A EP3973948A3 (en) | 2019-07-29 | 2019-07-29 | Cosmetic composition with combined filler and skin regenerative effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2019/070361 WO2021018377A1 (en) | 2019-07-29 | 2019-07-29 | Cosmetic composition with combined filler and skin regenerative effect |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP22152960.5A Division EP3973948A3 (en) | 2019-07-29 | 2019-07-29 | Cosmetic composition with combined filler and skin regenerative effect |
| EP22152960.5A Division-Into EP3973948A3 (en) | 2019-07-29 | 2019-07-29 | Cosmetic composition with combined filler and skin regenerative effect |
| EP22150089.5 Division-Into | 2022-01-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP3968948A1 true EP3968948A1 (en) | 2022-03-23 |
Family
ID=67742355
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19758620.9A Pending EP3968948A1 (en) | 2019-07-29 | 2019-07-29 | Cosmetic composition with combined filler and skin regenerative effect |
| EP22152960.5A Pending EP3973948A3 (en) | 2019-07-29 | 2019-07-29 | Cosmetic composition with combined filler and skin regenerative effect |
| EP20760391.1A Pending EP4003288A1 (en) | 2019-07-29 | 2020-07-29 | Cosmetic composition with combined filler and skin regenerative effect |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP22152960.5A Pending EP3973948A3 (en) | 2019-07-29 | 2019-07-29 | Cosmetic composition with combined filler and skin regenerative effect |
| EP20760391.1A Pending EP4003288A1 (en) | 2019-07-29 | 2020-07-29 | Cosmetic composition with combined filler and skin regenerative effect |
Country Status (2)
| Country | Link |
|---|---|
| EP (3) | EP3968948A1 (en) |
| WO (2) | WO2021018377A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117304368B (en) * | 2023-11-29 | 2024-03-01 | 杭州湃肽生化科技有限公司 | Composition of sodium hyaluronate and collagen pentapeptide and application thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1462876B1 (en) | 2003-03-28 | 2011-01-26 | Manufacture Roger Dubuis S.A. | Timepiece with a device for the display of two time zones |
| JP4271122B2 (en) | 2004-10-15 | 2009-06-03 | 財団法人 ひろしま産業振興機構 | Polynucleotides for recombinant protein production in silkworm |
| EP2033689A1 (en) * | 2007-08-22 | 2009-03-11 | Italfarmacia S.r.l. | Injectable dermatological composition for treatment of the wrinkles |
| US20130116411A1 (en) * | 2011-09-06 | 2013-05-09 | Allergan, Inc. | Methods of making hyaluronic acid/collagen compositions |
| AU2012332294B2 (en) | 2011-11-04 | 2017-09-07 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
| WO2013106715A1 (en) | 2012-01-13 | 2013-07-18 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
| WO2018144093A2 (en) * | 2016-11-03 | 2018-08-09 | Pinsky Mark A | Formulations for improved skin care |
| CN108261341A (en) * | 2018-02-12 | 2018-07-10 | 苏州纳晶医药技术有限公司 | Two-component is used to correct the long-acting water laser accunputure agent of whitening of wrinkle of skin |
| US11801329B2 (en) * | 2018-05-03 | 2023-10-31 | Collplant Ltd. | Dermal fillers and applications thereof |
-
2019
- 2019-07-29 EP EP19758620.9A patent/EP3968948A1/en active Pending
- 2019-07-29 WO PCT/EP2019/070361 patent/WO2021018377A1/en unknown
- 2019-07-29 EP EP22152960.5A patent/EP3973948A3/en active Pending
-
2020
- 2020-07-29 WO PCT/EP2020/071374 patent/WO2021018950A1/en unknown
- 2020-07-29 EP EP20760391.1A patent/EP4003288A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4003288A1 (en) | 2022-06-01 |
| EP3973948A2 (en) | 2022-03-30 |
| WO2021018950A1 (en) | 2021-02-04 |
| EP3973948A3 (en) | 2022-06-01 |
| WO2021018377A1 (en) | 2021-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6995946B2 (en) | Dermal filler composition containing antioxidants | |
| JP6125509B2 (en) | Dermal filler composition comprising an antioxidant | |
| KR102256061B1 (en) | Method for crosslinking hyaluronic acid, method for preparing an injectable hydrogel, hydrogel obtained and use of the obtained hydrogel | |
| JP5563984B2 (en) | Alloplast skin filler for injection and method of use | |
| ES2823650T3 (en) | Dermal filler compositions | |
| EP3107587B1 (en) | Dermocosmetic filler and uses thereof for aesthetic purposes | |
| CA2805008A1 (en) | Filler composition for tissue augmentation comprising a hydrogel of hyaluronic acid cross-linked with alkylene diamine | |
| US20200038552A1 (en) | Method of manufacturing and dermal filler compositions containing hyaluronic acid and hydroxyapatite | |
| WO2021077681A1 (en) | Hyaluronic acid gel composition for water optoinjection, and preparation method therefor | |
| US20230042665A1 (en) | Physical mix ha-collagen dermal fillers | |
| JP2014510590A (en) | Composition comprising a filler product and at least one bioabsorbable and biodegradable silica-based material | |
| JP2013525036A (en) | Alloplast skin filler for injection and method of use | |
| KR20220048906A (en) | Filler compositions | |
| EP3973948A2 (en) | Cosmetic composition with combined filler and skin regenerative effect | |
| Pirayesh et al. | Absorbable Soft Tissue Fillers: Core Characteristics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20211215 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20230519 |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230525 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |